We are monitoring the impact of COVID-19 on APAC CAR T cell Therapy Market Get in touch with us for detailed analysis Know More
Pulished Date September, 2020
ID: 10130
Share on
Share on

Asia Pacific CAR T cell Therapy Market Research Report - By Target Antigen, Products, Application, Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) – Industry Size, Share, Trends and Forecast (2020 to 2025)

Pulished: September, 2020
ID: 10130
Pages: 100

APAC CAR T cell Therapy Market Size (2020 to 2025)

The CAR T cell Therapy Market size in the Asia Pacific is estimated to grow at a robust CAGR from 2020 to 2025.

Increased funds from the government organizations and the adoption of advanced technologies in the hospitals and clinics are undoubtedly significant factors for the market to grow in the Asia Pacific. It is proven that CAR T cell therapy is very much efficient in treating cancer, and this is elevating the growth rate of the market enormously. Growing older people is one more factor propelling the CAR T cell therapy market's demand in the Asia Pacific. An increasing number of people suffering from chronic diseases is accelerating the size of the market. In the Asia Pacific, more than 2000 clinical trials were going on with this technique, which is solely enhancing the market demand. 

However, this treatment procedure's cost is very high, where ordinary people cannot afford is slowly impeding the growth rate of the CAR T cell therapy market in the Asia Pacific. Stringent rules and regulations by the government in approving new techniques are limiting the demand of the market. Besides, the shortage of skilled professionals in the laboratories to perform clinical trials is hampering the market's demand. Inadequate reimbursement policies in underdeveloped countries are likely to show a negative impact on the growth rate of the market. 

This research report on the Asia Pacific CAR T cell therapy market has been segmented and sub-segmented into the following categories:

By Target Antigen

  • CD20
  • EGFRV III
  • CD19
  • HER2
  • MESO
  • CD22
  • BCMA
  • GD2
  • CD30
  • HER1
  • CD33

By Application

  • Multiple Myeloma
  • Chronic Lymphocytic Leukemia
  • Mantle Cell Lymphoma
  • Follicular Lymphoma
  • Diffuse large B-cell lymphoma
  • Acute Lymphoblastic Leukemia

By Product

  • Allogeneic
  • Autologous

By Therapies:

  • Axicabtagene ciloleucel (Yescarta)
  • Tisagenlecleucel (Kymriah)

By End-User

  • Cancer Research Centers
  • Hospitals
  • Academic and Research Institutes
  • Pharmaceutical Companies
  • Biotechnology Companies
  • Contract Research Organizations

Country-Level Analysis:

Asia Pacific is estimated to reach the highest CAGR in the coming years. Growing knowledge over the availability of different treatment procedures through digital advertisements bolsters the CAR T cell therapy market's growth. 

China is leading with the highest shares of the market by owing to the increasing number of hospitals with excellent infrastructure. The launch of innovative techniques with advanced technologies is surging the demand of the market. According to the recent survey, around 4.3 million people have cancer in China. 

India is next to China in dominating the shares of the CAR T cell therapy market. The number of cancer cases in India is projected to surge in the coming years due to lifestyle changes. Increasing pharmaceutical companies and a rise in the number of clinical trials are fuelling the market's growth rate. The introduction of these techniques to treat cancer is elevating this market's demand for this country's extent.

Japan is esteemed to have significant growth opportunities in the coming years with the growing economy from the past few years. Also, focusing on improving the quality of healthcare services by introducing various techniques is boosting market demand.  

Notable companies in the APAC CAR T Cell Therapy Market profiled in this report are Mustang Bio, Inc., Celgene Corporation, Bluebird Bio, Inc., CARsgen Therapeutics, Ltd., Novartis International AG, Legend Biotech, Sorrento Therapeutics Inc., Kite Pharma, Inc., Immune Therapeutics, Bellicum Pharmaceuticals, Inc. and Pfizer, Inc.

  1. INTRODUCTION
    1. Market Definition
    2. Study Deliverables
    3. Base Currency, Base Year and Forecast Periods
    4. General Study Assumptions
  2. RESEARCH METHODOLOGY
    1. Introduction
    2. Research Phases
      1. Secondary Research
      2. Primary Research
      3. Econometric Modelling
      4. Expert Validation
    3. Analysis Design
    4. Study Timeline
  3. OVERVIEW
    1. Executive Summary
    2. Key Inferences
  4. DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES ANALYSIS
    1. Market Drivers
    2. Market Restraints
    3. Key Challenges
    4. Current Opportunities in the Market
  5. MARKET SEGMENTATION
    1. By Target Antigen
      1. CD20
      2. EGFRV III
      3. CD19
      4. HER2
      5. MESO
      6. CD22
      7. BCMA
      8. GD2
      9. CD30
      10. HER1
      11. CD33
      12. Y-o-Y Growth Analysis, By Target Antigen
      13. Market Attractiveness Analysis, By Target Antigen
      14. Market Share Analysis, By Target Antigen
    2. By Application
      1. Multiple Myeloma
      2. Chronic Lymphocytic Leukemia
      3. Mantle Cell Lymphoma
      4. Follicular Lymphoma
      5. Diffuse large B-cell lymphoma
      6. Acute Lymphoblastic Leukemia
      7. Y-o-Y Growth Analysis, By Application
      8. Market Attractiveness Analysis, By Application
      9. Market Share Analysis, By Application
    3. By Product
      1. Allogeneic
      2. Autologous
      3. Y-o-Y Growth Analysis, By Product
      4. Market Attractiveness Analysis, By Product
      5. Market Share Analysis, By Product
    4. By Therapies
      1. Axicabtagene ciloleucel (Yescarta)
      2. Tisagenlecleucel (Kymriah)
      3. Y-o-Y Growth Analysis, By Therapies
      4. Market Attractiveness Analysis, By Therapies
      5. Market Share Analysis, By Therapies
    5. By End User
      1. Cancer Research Centers
      2. Hospitals
      3. Academic and Research Institutes
      4. Pharmaceutical Companies
      5. Biotechnology Companies
      6. Contract Research Organizations
      7. Y-o-Y Growth Analysis, By End User
      8. Market Attractiveness Analysis, By End User
  6. GEOGRAPHICAL ANALYSIS
    1. Introduction
      1. Regional Trends
      2. Impact Analysis
      3. Y-o-Y Growth Analysis
      4. Market Attractiveness Analysis
      5. Market Share Analysis
    2. Asia Pacific
      1. India
      2. China
      3. Japan
      4. South Korea
      5. Australia
      6. New Zealand
      7. Thailand
      8. Malaysia
      9. Vietnam
      10. Philippines
      11. Indonesia
      12. Singapore
      13. Rest of APAC
  7. STRATEGIC ANALYSIS
    1. PESTLE analysis
      1. Political
      2. Economic
      3. Social
      4. Technological
      5. Legal
      6. Environmental
    2. Porter’s Five analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Consumers
      3. Threat of New Entrants
      4. Threat of Substitute Products and Services
      5. Competitive Rivalry within the Industry
  8. MARKET LEADERS' ANALYSIS
    1. Mustang Bio, Inc.,
      1. Overview
      2. Products
      3. Financials (subjected to availability based on company type)
      4. Recent Developments
      5. SWOT analysis
      6. Analyst View
    2. Celgene Corporation
    3. Bluebird Bio, Inc.
    4. CARsgen Therapeutics, Ltd.
    5. Novartis International AG
    6. Legend Biotech
    7. Sorrento Therapeutics Inc.
    8. Kite Pharma, Inc.
    9. Immune Therapeutics
    10. Bellicum Pharmaceuticals, Inc.
    11. Pfizer, Inc.
  9. COMPETITIVE LANDSCAPE
    1. Market share analysis
    2. Merger and Acquisition Analysis
    3. Agreements, collaborations and Joint Ventures
    4. New Product Launches
  10. MARKET OUTLOOK AND INVESTMENT OPPORTUNITIES
  11. APPENDIX
    1. List of Tables
    2. List of Figures
  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is booming, and to also identify the areas that are still untapped.
  • The segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the microenvironment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, vital financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia Pacific Global CAR T cell Therapy Market, By Target Antigen, From 2020 to 2025 (USD Million)
  2. Asia Pacific CD 20 Market, By Region, From 2020 to 2025 (USD Million)
  3. Asia Pacific EGFRV III Market, By Region, From 2020 to 2025 (USD Million)
  4. Asia Pacific CD 19 Market, By Region, From 2020 to 2025 (USD Million)
  5. Asia Pacific HER 2 Market, By Region, From 2020 to 2025 (USD Million)
  6. Asia Pacific MESO Market, By Region, From 2020 to 2025 (USD Million)
  7. Asia Pacific CD 22 Market, By Region, From 2020 to 2025 (USD Million)
  8. Asia Pacific BCMA Market, By Region, From 2020 to 2025 (USD Million)
  9. Asia Pacific GD 2 Market, By Region, From 2020 to 2025 (USD Million)
  10. Asia Pacific CD 30 Market, By Region, From 2020 to 2025 (USD Million)
  11. Asia Pacific HER 1 Market, By Region, From 2020 to 2025 (USD Million)
  12. Asia Pacific Global CAR T cell Therapy Market, By Application, From 2020 to 2025 (USD Million)
  13. Asia Pacific Multiple Myeloma Market, By Region, From 2020 to 2025 (USD Million)
  14. Asia Pacific Chronic Lymphocytic Leukemia Market, By Region, From 2020 to 2025 (USD Million)
  15. Asia Pacific Mantle Cell Lymphoma Market, By Region, From 2020 to 2025 (USD Million)
  16. Asia Pacific Follicular Lymphoma Market, By Region, From 2020 to 2025 (USD Million)
  17. Asia Pacific Diffuse large B-cell Lymphoma Market, By Region, From 2020 to 2025 (USD Million)
  18. Asia Pacific Acute Lymphoblastic Leukemia Market, By Region, From 2020 to 2025 (USD Million)
  19. Asia Pacific Global CAR T cell Therapy Market, By Product, From 2020 to 2025 (USD Million)
  20. Asia Pacific Allogeneic Market, By Region, From 2020 to 2025 (USD Million)
  21. Asia Pacific Autologous Market, By Region, From 2020 to 2025 (USD Million)
  22. Asia Pacific Global CAR T cell Therapy Market, By Therapies, From 2020 to 2025 (USD Million)
  23. Asia Pacific Axicabtagene Ciloleucel (Yescarta) Market, By Region, From 2020 to 2025 (USD Million)
  24. Asia Pacific Tisagenlecleucel (Kymriah) Market, By Region, From 2020 to 2025 (USD Million)
  25. Asia Pacific Global CAR T cell Therapy Market, By End-User, From 2020 to 2025 (USD Million)
  26. Asia Pacific Cancer Reasearch Centers Market, By Region, From 2020 to 2025 (USD Million)
  27. Asia Pacific Hospitals Market, By Region, From 2020 to 2025 (USD Million)
  28. Asia Pacific Academic and Research institutes Market, By Region, From 2020 to 2025 (USD Million)
  29. Asia Pacific Pharmaceutical Companies Market, By Region, From 2020 to 2025 (USD Million)
  30. Asia Pacific Biotechnology Companies  Market, By Region, From 2020 to 2025 (USD Million)
  31. Asia Pacific Contract Research Organizations Market, By Region, From 2020 to 2025 (USD Million)
  32. Japan Global CAR T cell Therapy Market, By Target Antigen, From 2020 to 2025 (USD Million)
  33. Japan Global CAR T cell Therapy Market, By Application, From 2020 to 2025 (USD Million)
  34. Japan Global CAR T cell Therapy Market, By Product, From 2020 to 2025 (USD Million)
  35. Japan Global CAR T cell Therapy Market, By Therapies, From 2020 to 2025 (USD Million)
  36. Japan Global CAR T cell Therapy Market, By End-User, From 2020 to 2025 (USD Million)
  37. China Global CAR T cell Therapy Market, By Target Antigen, From 2020 to 2025 (USD Million)
  38. China Global CAR T cell Therapy Market, By Application, From 2020 to 2025 (USD Million)
  39. China Global CAR T cell Therapy Market, By Product, From 2020 to 2025 (USD Million)
  40. China Global CAR T cell Therapy Market, By Therapies, From 2020 to 2025 (USD Million)
  41. China Global CAR T cell Therapy Market, By End-User, From 2020 to 2025 (USD Million)
  42. India Global CAR T cell Therapy Market, By Target Antigen, From 2020 to 2025 (USD Million)
  43. India Global CAR T cell Therapy Market, By Application, From 2020 to 2025 (USD Million)
  44. India Global CAR T cell Therapy Market, By Product, From 2020 to 2025 (USD Million)
  45. India Global CAR T cell Therapy Market, By Therapies, From 2020 to 2025 (USD Million)
  46. India Global CAR T cell Therapy Market, By End-User, From 2020 to 2025 (USD Million)
  47. Australia Global CAR T cell Therapy Market, By Target Antigen, From 2020 to 2025 (USD Million)
  48. Australia Global CAR T cell Therapy Market, By Application, From 2020 to 2025 (USD Million)
  49. Australia Global CAR T cell Therapy Market, By Product, From 2020 to 2025 (USD Million)
  50. Australia Global CAR T cell Therapy Market, By Therapies, From 2020 to 2025 (USD Million)
  51. Australia Global CAR T cell Therapy Market, By End-User, From 2020 to 2025 (USD Million)
  52. South Korea Global CAR T cell Therapy Market, By Target Antigen, From 2020 to 2025 (USD Million)
  53. South Korea Global CAR T cell Therapy Market, By Application, From 2020 to 2025 (USD Million)
  54. South Korea Global CAR T cell Therapy Market, By Product, From 2020 to 2025 (USD Million)
  55. South Korea Global CAR T cell Therapy Market, By Therapies, From 2020 to 2025 (USD Million)
  56. South Korea Global CAR T cell Therapy Market, By End-User, From 2020 to 2025 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample